Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors

Clinical Cancer Research

Volumn 15, Issue 10, 2009, Pages 3384-3395

  Castillo Ávila, Wilmar ^a   Piulats, Josep Maria ^a   Garcia Del Muro, Xavier ^a   Vidal, August ^b   Condom, Enric ^b   Casanovas, Oriol ^a   Mora, Josefina ^c   Ramon Germà, Josep ^a   Capellà, Gabriel ^a   Villanueva, Alberto ^a   Viñals, Francesc ^a,b,d  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; SUNITINIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CANCER TRANSPLANTATION; CHORIOCARCINOMA; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; GERM CELL TUMOR; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VASCULARIZATION; YOLK SAC;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; INDOLES; MALE; MICE; MICE, NUDE; NEOPLASMS, GERM CELL AND EMBRYONAL; NEOVASCULARIZATION, PATHOLOGIC; PYRROLES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TESTICULAR NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66149168686     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2170     Document Type: Article

References (36)

1. Carver BS, Sheinfeld J. Germ cell tumors of the testis. Ann Surg Oncol 2005;11:1-10. (Pubitemid 41504219)
2. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA 2008;299:672-684
3. Beyer J, Kramar A, Mandanas R, et al. Highdose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 1996;14: 2638-2645 (Pubitemid 26329647)
4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186
5. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932-936 (Pubitemid 43093958)
6. Shuhardja A, Hoffman H. Role of growth factors and their receptors on proliferation of microvascular endothelial cells. Microsc Res Tech 2003; 60:70-75 (Pubitemid 36055235)
7. Arora A, Scholar EM. Role of tyrosine kinase inhibitors incan cer therapy. J Pharmacol Exp Ther 2005;315:971-979 (Pubitemid 41635382)
8. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits c-KIT and platelet-derived growth factor receptor-β in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003;2:471-478
9. O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-3605 (Pubitemid 36857948)
10. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337
11. Prenen H, Cools J, Mentens N, et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006;12:2622-2627
12. Boüard S, Herlin P, Christensen JG, et al. Antiangiogenic and anti-invasive effects of sunitinib onexperimen tal human glioblastoma. Neurooncol 2007;9:412-423
13. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24. (Pubitemid 46630489)
14. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35. (Pubitemid 46630490)
15. Chow L, Eckhardt S. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25: 2858-2859 (Pubitemid 350002890)
16. Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007;13:1367-1373 (Pubitemid 46450424)
17. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007; 6:734-745 (Pubitemid 47338181)
18. McIntyre A, Summersgill B, Grygalewicz B, et al. Amplificationan d overexpression of the c-KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res 2005;65:8085-8089 (Pubitemid 41330569)
19. Viglietto G, Romano A, Maglione D, et al. Neovascularizationin humangerm cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. Oncogene 1996;13:577-587 (Pubitemid 26283854)
20. Basciani S, Mariani S, Arizzi M, et al. Expression of platelet-derived growth factor-A (PDGF-A), PDGF-B, and PDGF receptor-α and -β during human testicular development and disease. J Clin Endocrinol Metab 2002;87: 2310-2319 (Pubitemid 34521525)
21. Trigo JM, Tabernero JM, Paz-Ares L, et al. Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer 2000;88:162-168 (Pubitemid 30027692)
22. Aparicio J, Germà JR, García del Muro X, et al. Risk-adapted management for patients with clinical stage I seminoma: the second Spanish Germ Cell Cancer Cooperative Group Study. J Clin Oncol 2005;23:8717-8723 (Pubitemid 46211516)
23. Mora J, Gascón N, Tabernero JM, Germà JR, González F. α-Fetoprotein-concanavalin A binding as a marker to discriminate between germ cell tumours and liver diseases. Eur J Cancer 1995;31:2239-2242 (Pubitemid 26050565)
24. Mora J, Gascón N, Tabernero JM, Rodríguez- Espinosa J, González-Sastre F. Different hCG assays to measure ectopic hCG secretionin bladder carcinoma patients. Br J Cancer 1996; 74:1081-1084 (Pubitemid 26333910)
25. Bentas W, Beecken WD, Glienke W, Binder J, Schuldes H. Serum levels of basic fibroblast factor reflects disseminated disease in patients with testicular germ cell tumors. Urol Res 2003;30:390-393 (Pubitemid 36285657)
26. Aigner A, Brachmann P, Beyer J, et al. Marked increase of the growth factors pleiotrophin and fibroblast growth factor-2 inserum of testicular cancer patients. Ann Oncol 2003;14:1525-1529 (Pubitemid 37304608)
27. Fukuda S, Shirahama T, Imazono Y, et al. Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease. Cancer 1999;85:1323-1330 (Pubitemid 29125086)
28. Devouassoux-Shisheboran M , Mauduit C, Tabone E, Droz JP, Benahmed M. Growth regulatory factors and signalling proteins in testicular germ cell tumors. APMIS 2003;111:212-224 (Pubitemid 36566691)
29. Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004;7:225-233
30. McGary EC, Weber K, Mills L, et al. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 2002;8:3584-3591 (Pubitemid 35340737)
31. Potapova O, Laird A, Nannini M, et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 2006; 5:1280-1288 (Pubitemid 43881321)
32. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003; 111:1287-1295 (Pubitemid 36554699)
33. Piulats JM, García del Muro X, Germà JR. New drugs in the treatment of germ cell tumors. Cancer Chemother Rev 2007;2:232-240
34. Einhorn LH, Brames MJ, Heinrich MC, Corless CL, Madani A. Phase II study of imatinib mesylate inchemotherapy refractory germ cell tumors expressing C-KIT. Am J Clin Oncol 2006; 29:12-13 (Pubitemid 44356708)
35. Abrams TJ, Murray LJ, Pesenti E, et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with standard of care: therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003;2:1011-1021
36. Kollmannsberger C, Nochols C, Bokemeyer C. Recent advances in management of patients with platinum-refractory testicular germ cell tumors. Cancer 2006;106:1217-1225 (Pubitemid 43363897)